Key result
One or more doses of rotavirus vaccine demonstrated a direct vaccine effectiveness of 87% to 92% each year in preventing rotavirus gastroenteritis hospitalizations among privately insured US children.
Why the study?
Does rotavirus vaccination prevent gastroenteritis hospitalizations in privately insured US children?
Cohort (n=905,718)
Does rotavirus vaccination prevent gastroenteritis hospitalizations in privately insured US children?
Effect estimate: Vaccine effectiveness 87%-92%
Rotavirus vaccination provides high direct effectiveness (87-92%) against rotavirus gastroenteritis hospitalizations, with additional indirect protection benefits.
No takes yet. Share an insight, caveat, or question.
May support rotavirus vaccination in insured US children; extends observational data but leaves causal confirmation open.
We demonstrate how direct, indirect, total, and overall effectiveness estimates and absolute benefits of rotavirus vaccines vary through the years following vaccine introduction. Privately insured US children in a large claims database were followed from age 8 months until they 1) experienced a hospitalization for rotavirus or acute gastroenteritis; 2) lost continuous health plan enrollment; 3) turned 20 months of age; or 4) reached the end of the study period. Vaccine effectiveness estimates in preventing rotavirus and acute gastroenteritis hospitalizations were estimated using Cox proportional hazards regression, stratified by calendar year and adjusted for birth month. Incidence rate differences were estimated to determine the absolute number of gastroenteritis hospitalizations prevented in the cohort. Among 905,718 children, 51%, 66%, 80%, and 86% received 1 or more doses of rotavirus vaccine in each year from 2007 to 2010. The direct vaccine effectiveness of 1 or more doses of rotavirus vaccine in preventing rotavirus gastroenteritis hospitalizations ranged from 87% to 92% each year. Accounting for indirect protection increased estimates of vaccine effectiveness by an additional 3%-8% among those vaccinated. Failing to account for population-level vaccine benefits in 2010, when circulation of rotavirus was low, could underestimate the sustained impact of the vaccine program.
Panozzo et al. (2014) conducted a cohort in Rotavirus and acute gastroenteritis (n=905,718). Rotavirus vaccine (≥1 dose) vs. Unvaccinated children was evaluated on Rotavirus and acute gastroenteritis hospitalizations (Vaccine effectiveness 87%-92%). One or more doses of rotavirus vaccine demonstrated a direct vaccine effectiveness of 87% to 92% each year in preventing rotavirus gastroenteritis hospitalizations among privately insured US children.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: